Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28607233 | 0.93 | BTK (0.39) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL4706132 | 0.93 | BTK (0.47) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL1771267 | 0.93 | BTK (0.51) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL3918859 | 0.91 | BTK (0.46) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL28558390 | 0.89 | BTK (0.42) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL27914275 | 0.88 | BTK (0.38) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL28749381 | 0.88 | BTK (0.38) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL15881327 | 0.88 | RECQL (0.39) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL4961405 | 0.87 | BTK (0.40) | BTKKMT2AALDH1A1MEN1TSHR | |
| SCHEMBL1282302 | 0.87 | MEN1 (0.45) | BTKKMT2AALDH1A1MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112770782-A | Sustained delivery of angiopoietin-like 3 polypeptides | 诺华股份有限公司 | 2021-05-07 | — | — | CN | claimed |
| CN-110603060-A | Sustained release delivery system comprising traceless linker | 诺华股份有限公司 | 2019-12-20 | — | — | CN | claimed |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4583867-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | Latigo Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2024261328-A1 | AMIDE-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2024-12-26 | — | — | WO | disclosed |
| US-20240190846-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC. | 2024-06-13 | — | — | US | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024054622-A2 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | KOZIKOWSKI ALAN P | 2007-07-12 | — | — | US | disclosed |
| US-7202279-B1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | GEORGETOWN UNIVERSITY (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1816548-A | cyclopropyl substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO INC (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1630633-A | N-biphenylmethylaminocycloalkane carboxamide derivatives with substituents on the methyl group thereof as bradykinin antagonists | MERCK & CO INC (US) | 2005-06-22 | — | — | CN | disclosed |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK SHARP & DOHME CORP. | 2005-02-17 | — | — | US | disclosed |
| EP-1497317-A2 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1497316-A2 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087070-A2 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087069-A2 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | BTK 207/4885KMT2A 1106/4885ALDH1A1 246/4885 |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | BTK 1871/4885KMT2A 4582/4885ALDH1A1 1478/4885 |
| US-20070161640-A1 | Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders | BDNF, PMP22, ADAM17 | BTK 3235/4885KMT2A 1699/4885ALDH1A1 3513/4885 |
| US-12291518-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | BTK 4229/4885KMT2A 4108/4885ALDH1A1 1862/4885 |
| US-20250320197-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | BTK 4229/4885KMT2A 4108/4885ALDH1A1 1862/4885 |
| US-20240190846-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | BTK 4229/4885KMT2A 4108/4885ALDH1A1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.